Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.12.2013 | comment | Ausgabe 4/2013

memo - Magazine of European Medical Oncology 4/2013

ASCO 2013—new concepts and the path to individualized therapy

memo - Magazine of European Medical Oncology > Ausgabe 4/2013
Univ. Prof. Dr. Heinz Zwierzina


At American Society of Clinical Oncology’s 2013 meeting, the clinical development of innovative drugs targeting the immune system and progress in biomarker research represented some of the highlights. During recent years, immunomodulatory agents have become a very active field in clinical cancer research. After the successful development of the anti-cytotoxic T-lymphocyte antigen 4 (CTLA4) antibody ipilimumab in melanoma, the “programmed cell death protein 1” pathway is expected to become a cornerstone in several tumor types. One key challenge for anticancer treatment, in general, is the definition of biomarkers and the further individualization of therapy. Progress in molecular phenotyping and in serum proteomics as predictive markers was reported.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 4/2013

memo - Magazine of European Medical Oncology 4/2013 Zur Ausgabe